digital

therapeutics

+

digital clinic

 MAKING MUSCLE AND BRAIN WORK TOGETHER

 

JOGO uses an app and wearable technology that leverage AI and VR to treat pain and neuromuscular conditions by providing treatment protocols and games that can be adapted for muscle relaxation, movement coordination, and neuromuscular re-education, using the clinically proven science of neuroplasticity.

 

JOGO therapy is provided by JOGO's own Digital Clinic via telemedicine and in clinics affiliated with JOGO Health.

 

JOGO is FDA registered and FDA 510 (k) exempt. JOGO services are covered by Medicare and most commercial insurance plans.

Pathways between two neurons get damaged for patients with neuromuscular conditions

path_damaged.png

JOGO exercises utilize neuroplasticity – development of new pathways between neurons

jogo_excercise.png

Brain creates new pathways to work with inactive muscles or address pain

path_damaged.png

Our Story

​Someone in the United States has a stroke every 40 seconds. Every year, worldwide, more than 15 million people have a stroke, 795,000 people in the United States alone. Three in 1000 children are born with cerebral palsy.  35% of adult women and 75% of multiple sclerosis patients have stress urinary incontinence (SUI).  With nine years of tireless research and testing, we have created JOGO as a potential prescription digital therapy to treat more than ten neuromuscular conditions such as these. In 2019, JOGO received the patent for this innovation from United States Patent and Trademark Office (USPTO).

The word "jogo" means “game” in Portuguese and is our tribute to Dr. Joe Brudny and Dr. Gordon Silverman, whose pioneering work paved the way for our product. JOGO is the result of the continuing work of entrepreneurs, product design specialists, technology enthusiasts, physical therapy professionals, physiatrists, data scientists, and game designers.

JOGO is EVIDENCE-DRIVEN

128 patients with incontinence (stress, urge or post-prostate surgery) treated with JOGO Digital Therapeutics had an average of 90%  improvement and either ended the use of overactive bladder drugs or avoided surgery.

9 out of 10  patients with pelvic organ prolapse avoided surgery.

 
 
  • Twitter
  • YouTube
  • Facebook

CONTACT US

JOHNSON & JOHNSON INNOVATION (JLABS)

 UNIVERSITY OF PENNSYLVANIA PENNOVATION CENTER,

3401 GRAYS FERRY AVE, PHILADELPHIA, PA 19146

NEW JERSEY OFFICE:

991 US 22, SUITE #200, BRIDGEWATER, NJ 08807

TEL: +908-291-2043  |  INFO@JOGOHEALTH.COM

arrow&v

Thanks! Message sent.